Type 2 Diabetes T2d clinical trials

Explore recruiting type 2 diabetes t2d clinical trials.

Recruiting type 2 diabetes t2d studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Type 2 Diabetes T2d trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. oral solution formulations in healthy volunteers

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pregnancy Outcomes: Effects of Metformin Study (POEM Study) a long term randomized controlled parallel group study in gestational diabetes mellitus

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

Italy, Croatia, Hungary, Slovakia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) once weekly versus placebo in participants with type 2 diabetes and painful diabetic peripheral neuropathy

Norway, Denmark, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Type 2 Diabetes T2d trials by city

Type 2 Diabetes T2d in Toronto Type 2 Diabetes T2d in Vancouver Type 2 Diabetes T2d in Montreal Type 2 Diabetes T2d in Calgary Type 2 Diabetes T2d in Edmonton Type 2 Diabetes T2d in Ottawa Type 2 Diabetes T2d in Winnipeg Type 2 Diabetes T2d in Quebec City Type 2 Diabetes T2d in Hamilton Type 2 Diabetes T2d in Kitchener Type 2 Diabetes T2d in London Type 2 Diabetes T2d in Halifax Type 2 Diabetes T2d in New York Type 2 Diabetes T2d in Los Angeles Type 2 Diabetes T2d in Chicago Type 2 Diabetes T2d in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease